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Immunotherapy represents a new treatment paradigm
that may have clinical activity in SCLC. Multiple lines of
evidence suggest that SCLC tumors may be immuno-
genic. First, a subset of SCLCs are associated with pro-
duction of auto-antibodies or paraneoplastic syndromes,
and production of auto-antibodies predicts a higher
likelihood of complete response to ﬁrst-line chemo-
therapy and prolonged survival (Graus et al., 1997).
Second, higher ratios of circulating T effector cells to T
regulatory cells have been observed in patients with
earlier stage disease and correlate with prolonged
response to therapy (Koyama et al., 2008). Third,
although expression of programmed death ligand-1 (PD-
L1) is low on SCLC tumor cells, PD-L1 expression is
observed on tumor-inﬁltrating macrophages and is
correlated with the presence of tumor-inﬁltrating lym-
phocytes (Schultheis et al., 2015).
Clinically, SCLCs are associated with a history of sig-
niﬁcant tobacco exposure. In patients with non-small cell
lung cancer (NSCLC), response rates to inhibitors of the
immune checkpoint programmed death 1 (PD-1) recep-
tor are higher in current or former smokers compared to
never or minimal smokers. This increased response rate
is attributed to a higher mutational burden of these
carcinogen-associated tumors, leading to expression of
immunogenic neoantigens (Rizvi et al., 2015). Indeed,
SCLCs are characterized by a high somatic mutation
burden (George et al., 2015). This is likely largely
attributable to the carcinogenic effects of tobacco expo-
sure, though genomic instability may also be potentiated
by the universal loss of the tumor suppressor gene Tp53.
On the basis of these preclinical observations,
several clinical trials are now underway to assess role
of immunotherapy in SCLC. Emerging data suggest that
immune checkpoint inhibitors may have meaningful
clinical activity in this disease. CheckMate 032
(NCT01928394) is a phase 1/2 trial of nivolumab
either alone or in combination with ipilimumamb in
various tumors. Calvo et al. (ESMO, 2015) recently
presented preliminary ﬁndings from this study,
including an overall response rate of 12.7% with
nivolumab and 31.1% with nivolumab plus ipilimumab.
In a separate phase 1b study, Keynote-028
(NCT02054806), Ott et al. (ASCO, 2015) reported an
overall response rate of 35% among PD-L1 positive
SCLC patients treated with the PD-1 inhibitor pem-
brolizumab. Other inhibitors of PD-1, PD-L1 and CTLA-
4 are also in clinical development. The durability of
responses to immune checkpoint inhibitors is not yet
well established, and close monitoring for signs/
symptoms of paraneoplastic syndromes and autoim-
mune disease is necessary. Current and future trialsutilizing immune checkpoint inhibitors and other
modulators of the immune response will further
explore clinical activity, biomarkers, toxicities, and the
role of combination strategies in SCLC.Using stem cell biology to design
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Stem cell biology is integral to understanding the
development and treatment responses of lung cancers.
Our laboratories used ideas from stem cell biology to
explore one of the ﬁrst genetic mouse models of the
lung squamous cell carcinoma, driven by conditional
bialleleic inactivation of Stk11 (Lkb1) and Pten in the
murine lung. Cells that could serially transplant disease
(i.e. cancer stem cells) expressed markers of basal cells,
the upper airway stem cells, and highly expressed the
immune evasion molecule PD-L1. This was in contrast
to the lung adenocarcinoma stem cells from the Kras/
p53 mouse model that rely upon other pathways and
share characteristics of distal lung stem cells. Since
anti-PD1 blockade has shown promise in treating lung
squamous cell carcinomas, we are now exploring if
anti-PD1 targets cancer stem cells, and if so, in what
genotypes and contexts. We have also used ideas from
stem cell biology to build a rationale for combining
epigenetic therapies with common chemotherapies. It
is often found that cancer stem cells are resistant to
chemotherapy, and combination of chemotherapies
with targeted therapies could improve treatment out-
comes. Expression of the histone methyltransferase
EZH2 in lung tumors is correlated with a poor survival
of lung cancer patients, and is therefore an attractive
targeted therapy candidate. Because EZH2 is highly co-
expressed with the Topoisomerase II (TopoII) gene
TOP2A in lung cancers, we examined whether EZH2
inhibition synergized with the common chemotherapy
etoposide, which targets TopoII. We found that lung
cancers with activating mutations in EGFR, or with
inactivating mutations in the BAF complex member
BRG1, were both sensitized to etoposide by EZH2 in-
hibition. We are now exploring the mechanism through
which BRG1 loss of function lung cancers, which
represent up to 40% of lung adenocarcinomas, are
speciﬁcally sensitized to etoposide by EZH2 inhibition.
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concepts can help to design precision medicine op-
portunities for the genetically complex disease of non-
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Submillisecond pulses of radiation have been shown to
generate less exchange chromosomal aberrations [1, 2]
and a smaller extent of delayed cell death [3, 4] than
continuous irradiation delivered at conventional
dose-rate. This prompted us to determine whether
and how pulsed irradiation affects the response of
normal lung tissue in vivo. For this purpose, C57BL/
6J mice were given a single dose of 17 Gy of 4.5 MeV
electrons in bilateral thorax exposure either at a
high (> 60 Gy/s, beam-on time < 0.5 s, FLASH) or
conventional dose-rate (0.03 Gy/s, beam-on time 8
min, CONV) using an experimental linear electron
accelerator established in the Research Division of
Institut Curie at Orsay (France). DNA damage
response, apoptosis and ﬁbrosis development were
subsequently analyzed at suitable times in the two
modes of irradiation. The anti-tumor efﬁciency was
also evaluated in vivo with two xenografts (HBCx-
12A, HEp-2) and one syngeneic, orthotopic carcinoma
(TC1-Luc). The results indicate that, in the hours
following irradiation, FLASH-irradiated lungs present
less DNA damages and less apoptosis than lungs
irradiated at a conventional dose-rate. Furthermore,
compared to the classical radiation-induced lung
ﬁbrosis observed past 16-weeks after CONV
irradiation, analysis of FLASH-treated lungs did not
show any histological sign of ﬁbrosis nor activation
of the TGF-beta pathway. However, FLASH irradiation
was as efﬁcient as CONV treatment in controlling
tumor growth. Taken together, these results show
that FLASH irradiation selectively spares normal lung
tissue without any loss of the anti-tumor activity [5].
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Malignant cancers are characterized by microenviron-
mental heterogeneity, which is a leading cause of genomic
heterogeneity. Microenvironmental heterogeneity can be
viewed radiographically, wherein non-uniform patterns
of enhancement or attenuation can be associated with
poor outcome. In order to systematically investigate this,
the process of “Radiomics” extracts quantitative ﬁrst,
second and higher order image feature data that can be
statistically mined along with patient data for diagnostic,
predictive and prognostic, models. The radiomics enter-
prise is divided into ﬁve processes with deﬁnable inputs
and outputs: (i) image acquisition and reconstruction; (ii)
image segmentation and rendering; (iii) feature extraction
and qualiﬁcation; (iv) databases and data sharing; and (v)
informatics analyses. Each of these steps poses discrete
challenges that have to be met. Even though this ﬁeld is
still emerging, translationally-directed classiﬁer models
have been generated in detecting and diagnosing a num-
ber of cancer subtypes.
To date, the radiomics effort has focused on computer-
derived “agnostic” (e.g. texture) and radiologist-derived
“semantic” image features, which quantify indescribable
and describable features, respectively. These image
features number in the hundreds and have been
shown to have high prognostic value in both non-small
cell lung cancer, NSCLC, and are being used to classify
indeterminate lung nodules in lung cancer screening CTs.
In NSCLC, prognostic models have been developed for
patients treated with surgery, radiotherapy, or with
targeted therapies. In each of these cases, binary clas-
siﬁers have been used to predict response and/or sur-
vival with accuracies > 80%. In addition, radiomic
features have also been used to predict EGFR and KRAS
mutation status in NSCLC, also with accuracies > 80%.
Current challenges for the nascent ﬁeld of radiomics
include development of a core lexicon of features,
furthering the development and inter-institutional
harmonization of computer-extracted features, and
harmonization of image acquisition parameters for
reduced variance.
